EHA Unplugged

Join us for this inspirational interview with prof. Jan Cools from KU Leuven in Belgium who received the EHA 2025 Education & Mentoring Award. Prof. Cools describes his approach to mentoring students and scientists, emphasizing the aspects that he finds most crucial in this role. Tune in to hear his thoughts about the future of mentoring, the place artificial intelligence may take in it and th...

In this episode, we sit down with prof. Khaled Musallam from Burjeel Medical City in United Arab Emirates who discusses his extensive work to improve care for patients with thalassemia. Prof. Musallam’s research and clinical contributions have reshaped the management of both non-transfusion-dependent thalassemia (NTDT) and transfusion-dependent thalassemia (TDT). Tune in to hear his views on the c...

Join us for this discussion between Robin Doeswijk, EHA European Affairs and prof. John Gribben from Barts Cancer Institute in the United Kingdom on the topic of equity in care of patients with hematologic malignancies. This discussion follows the recently published “European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological Malignancies”. Tune in to hear how this c...

Join us for this captivating interview with Prof Kirsten Grønbæk from University of Copenhagen in Denmark, as she discusses her outstanding career in the field of hematology, both in research and in the clinics. Listen to how the interests of Prof Grønbæk evolved, leading her from the initial focus on epigenetics in lymphomas to MDS in the later years of her career. Prof Grønbæk reflects on the cu...

In this episode, we sit down with Prof. Maria Domenica Cappellini from the University of Milan in Italy, as she discusses her inspiring career as a hematologist specializing in the management of patients with thalassemia. Listen to the compelling story of how Prof. Cappellini’s interest in thalassemia started and how her relentless stride for the best possible care for her patients has helped to t...

Explore the latest breakthroughs in gene therapy for sickle cell disease and beta thalassemia with Dr. Stefano Rivella, hematologist and research faculty at Children's Hospital of Philadelphia.   In this episode, Dr. Rivella discusses the science behind FDA-approved therapies, compares gene addition and gene editing approaches, and shares insights on clinical safety, efficacy, and future innovatio...

Join us for this insightful interview with prof. Hartmut Döhner from University Hospital Ulm in Germany who tells about most recent developments in the management of older and unfit patients with AML. Prof. Döhner discusses all key aspects of the management including assessing patient fitness, genetic risk classification, and the choice of treatment, among which also the emerging therapies. Tune i...

Join EHA President prof. Konstanze Döhner from University Hospital Ulm in Germany who discusses the most recent developments in the management of young and fit patients with AML. Tune in to hear about the diagnostic workup, risk stratification, treatment and the evolving role of measurable residual disease (MRD) measurements in clinical decision making in this group of patients. Prof. Döhner also...

Listen as Prof. Christian Chabannon from Aix Marseille Université in France who tells about GoCART Coalition in this new podcast episode. The main goal of this coalition, which unites expertise from many fields, is to promote access to novel cellular therapies, such as CAR T-cells. Prof. Chabannon explain how GoCART is working on reaching this goal by generating new clinical insights, improving st...

Jan Geissler from Germany tells about his work as a patient advocate in the field of hematological malignancies. As a cancer survivor, patient advocate and patient engagement expert, Jan has been working tirelessly for many years in organizations such as European Patients Academy (EUPATI), Patvocates and many others. Listen to Jan’s passionate call for a collaborative spirit to achieve the best ou...

Prof. Maria Themeli tells about most recent developments in the field of “off-the-shelf” CAR T-cells. As the clinical success of advanced cellular therapies is growing, so is the need for broader access to these treatments. Listen as Prof. Themeli summarize the state-of-the-art technology that aims to generate “off-the-shelf” CAR T-cells from sources such as induced pluripotent stem cells (iPSCs)...

Join dr. Carmen Sanges from University Clinic Würzburg in Germany as she tells us about AIDPATH. This collaborative initiative is dedicated to improving access to advanced cellular therapies by employing artificial intelligence (AI) in the production process. Listen to dr. Sanges explain how AI technology is used to integrate patient-specific information and biomarkers to optimize CAR-T therapy. T...

Join us for this inspiring interview with prof. Elizabeth Macintyre from Université Paris Cité in France who tells us about her professional journey in hematology. Listen to prof. Macintyre discuss her views on the current state and future directions of advanced diagnostics in malignant hematology and their implications for healthcare management and the training of young specialists. Tune in to he...

Join Professor Kirsten Gronbaek and Professor Uwe Platzbecker as they discuss the complexities behind the classification and prognostication of low-risk myelodysplastic syndromes (MDS). They dive into the historical context of MDS classification, the evolution of prognostic indexes such as IPSS and IPSSM, and the implications of recent molecular findings.   This conversation highlights the challen...

Join host Professor Kirsten Gronbaek and guest Professor Arjan van de Loosdrecht as they dive into the complexities of measurable residual disease (MRD) monitoring in myelodysplastic syndromes (MDS) and myeloid cancers. Professor van de Loosdrecht explains the transition from minimal to measurable residual disease, the significance of MRD in predicting disease outcomes, and the various techniques...

In this episode, we sit down with prof. Martin Dreyling from the Ludwig-Maximilians-University in Munich who talks about his professional journey in hematology as a clinician and a researcher. Listen to prof. Dreyling as he recalls his contributions to the field of lymphoma, and in particular mantle cell lymphoma, that resulted in novel therapeutic approaches. The ongoing emphasis on the cross-bor...

In this episode, prof. Kirsten Gronbaek and dr. Shahram Kordasti discuss the role of immune dysfunction in MDS. With the improving understanding of complex pathophysiology of MDS, the major role of the immune system in this process is becoming increasingly apparent. Listen to dr. Kordasti discuss the multifactorial interactions between the malignant clones and the inflammatory environment, manifes...

In this interview, dr. Maria del Mar Mañu Pereira from Vall d’Hebron Research Institute in Spain talks about the Rare Anemia Disorders European Epidemiological Platform (RADeep). RADeep is an initiative of ERN-EuroBloodNet and functions as an umbrella for both new and already existing European patients' registries in rare anemia disorders.   Listen to dr. Mañu Pereira talk about the history of RAD...

Prof. Antonio Almeida from Hospital da Luz in Lisbon takes us through his professional journey in hematology as a clinician and educator, and his current role as the President of EHA. Listen to prof. Almeida recount his professional path that allowed him to experience various facets of hematological clinical practice in the UK and Portugal. Alongside his career as a hematologist, prof. Almeida cul...

Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options. He uses the example of targeting NLRP3/IL-1...

Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be add...

In this episode, Dr. Onima Chowdhury, a hematologist from the University Hospital in Oxford, talks about the diagnostic workup of Myelodysplastic Syndromes (MDS). With a focus on both clinical practice and research, Dr. Chowdhury outlines the essential steps and tests required for diagnosing MDS, discusses the role of morphology, cytogenetics, and the significance of NGS panels in the diagnostic p...

Join us for this insightful interview with prof. Brian Huntly from the University of Cambridge who tells about his professional journey in hematology as a clinician, scientist and educator. Listen to prof. Huntly discuss his important contributions to the field of leukemia stem cell biology in the context of current understanding of cell biological hierarchies and leukemia development. Prof. Huntl...

In this podcast, Prof Dame Lesley Fallowfield and Prof Clemens Wendtner discuss patient mental health and communication in the context of Chronic Lymphocytic Leukemia (CLL) treatment. They explore the psychological impact of CLL and leukemia in general, the importance of patient communication, and the need for integrated mental health support.  The conversation highlights the challenges of explain...

Join us for an insightful interview with patient advocates Miriam Santos Freire (sickle cell disease) and Loris Brunetta (beta-thalassemia major). Benefit from their experiences as they discuss with our host Isabel Olivera-Martinez the promises and challenges of gene therapy for these conditions. Listen to their experiences of living with these genetic conditions while they highlight the dispariti...